Palvella Therapeutics’ (PVLA) Buy Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research report report published on Wednesday morning,Benzinga reports. Chardan Capital currently has a $240.00 price objective on the stock.

Other research analysts have also issued reports about the stock. Canaccord Genuity Group set a $232.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Friday, September 25th. HC Wainwright restated a “buy” rating on shares of Palvella Therapeutics in a research report on Tuesday, October 20th. William Blair assumed coverage on shares of Palvella Therapeutics in a research note on Friday, October 16th. They issued an “outperform” rating on the stock. Finally, Truist Financial set a $207.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $209.79.

Palvella Therapeutics Stock Down 3.6%

Shares of NASDAQ PVLA opened at $146.15 on Wednesday. Palvella Therapeutics has a 1 year low of $71.55 and a 1 year high of $161.38. The stock’s 50-day simple moving average is $141.47 and its 200-day simple moving average is $126.70.

Palvella Therapeutics (NASDAQ:PVLA) last released its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.35). Research analysts forecast that Palvella Therapeutics will post -6.41 earnings per share for the current fiscal year.

Insider Buying and Selling at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,313 shares of the company’s stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $124.58, for a total transaction of $537,313.54. Following the completion of the sale, the chief operating officer directly owned 2,165 shares in the company, valued at $269,715.70. This represents a 66.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director George Jenkins sold 13,352 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $151.96, for a total transaction of $2,028,969.92. Following the completion of the transaction, the director owned 161,893 shares in the company, valued at $24,601,260.28. This trade represents a 7.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 61,056 shares of company stock valued at $8,756,946 in the last ninety days. 17.20% of the stock is currently owned by company insiders.

Institutional Trading of Palvella Therapeutics

Large investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. raised its stake in Palvella Therapeutics by 31.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,783 shares of the company’s stock worth $248,000 after buying an additional 426 shares in the last quarter. Sterling Capital Management LLC raised its holdings in Palvella Therapeutics by 907.7% in the third quarter. Sterling Capital Management LLC now owns 393 shares of the company’s stock worth $54,000 after purchasing an additional 354 shares in the last quarter. Avior Wealth Management LLC purchased a new stake in shares of Palvella Therapeutics during the third quarter valued at about $212,000. Arizona State Retirement System lifted its position in shares of Palvella Therapeutics by 30.9% during the second quarter. Arizona State Retirement System now owns 2,765 shares of the company’s stock valued at $423,000 after buying an additional 652 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in shares of Palvella Therapeutics in the 2nd quarter valued at about $35,000. 40.11% of the stock is owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.

The company’s development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets.